Immediate Impact

12 by Nobel laureates 23 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

Pharmacology and Clinical Development of Factor XI Inhibitors
2023 Standout
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
2020 Standout
2 intermediate papers

Works of Maxwell D. Cummings being referenced

Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor
2014
Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target
2010
and 2 more

Author Peers

Author Last Decade Papers Cites
Maxwell D. Cummings 1545 451 433 670 568 52 2.8k
M.M. Cherney 1893 227 351 776 360 75 3.4k
Priscilla L. Yang 2238 777 377 875 581 48 4.6k
Magali Mathieu 1494 200 312 594 218 37 3.0k
Hans E. Parge 2024 549 584 373 428 44 3.7k
Kent D. Stewart 1251 460 295 553 953 90 3.1k
Paul R. Caron 3932 479 716 426 260 39 5.2k
Krzysztof Appelt 2211 589 69 717 727 85 3.9k
Warren M. Kati 1595 173 722 1373 655 80 3.4k
Tarek S. Mansour 2217 432 326 580 2391 147 4.9k
Paula M.D. Fitzgerald 1456 303 41 990 624 37 2.9k

All Works

Loading papers...

Rankless by CCL
2026